Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fungofort
- Development stage
- Unknown
- Lead developer
- Nassington
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Fungofort is a topical antifungal cutaneous spray solution containing fluconazole, a triazole-class small molecule. It is indicated for the treatment of dermatomycoses caused by dermatophytes or yeasts, including tinea pedis (athlete's foot), tinea manuum, tinea corporis, tinea cruris, tinea versicolor, erythrasma, and Candida skin infections. Fungofort works by inhibiting the fungal enzyme lanosterol 14α-demethylase (CYP51), which is critical for ergosterol biosynthesis in fungal cell membranes. Developed by Nassington and manufactured by Cana Laboratories, Fungofort is registered and available in Greece as 0.5% and 1.0% w/v formulations for once-daily topical application.
- Brand names
- Fungofort
- Other names
- fluconazole cutaneous spray
02
Targets
CYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on Fungofort.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fungofort.